Article

Letrozole as a Treatment of Endometrial Cancer

Letrozole is a drug that blocks estrogen production, which causes endometrial cancer to grow in some cases. This study will examine whether the investigators may be able to predict which patients might benefit from Letrozole treatment by studying the different forms of the estrogen-receptor molecule that exist within the cancer tissues.

Study Type: Interventional

Age/Sex Requirement: 40 years+ (female)

Sponsor: University of California, Davis

Purpose: Letrozole is a drug that blocks estrogen production, which causes endometrial cancer to grow in some cases. This study will examine whether the investigators may be able to predict which patients might benefit from Letrozole treatment by studying the different forms of the estrogen-receptor molecule that exist within the cancer tissues. The study will be monitoring changes in estradiol level and apoptosis before treatment with Letrozole and at around 3 weeks following treatment.

Click here to learn more about this clinical trial.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Linda Gillam, MD, MPH | Credit: Atlantic Health System
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Allysa Saggese, NP | Credit: Weill Cornell Medicine
Zobair Younossi, MD, MPH | Credit: American College of Gastroenterology
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.